NC-DOLE-FOOD-NC
Dole Food Company announced today that in an effort to help with the COVID-19 crisis, Dole and its associated growers have so far donated more than two million pounds of fresh produce to recipients along its supply chain, from local food banks in the U.S. to the communities in Latin America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200416005885/en/
“The virus is ruthless, and we have seen the brutal impact it has had on people—directly to their health and their income,” stated Johan Linden, CEO of Dole Food Company. “We want to answer the needs of the communities around our operations and do what we can to strengthen them during this moment of hardship.”
Dole recognizes these donations alone will not solve the food needs issue brought on by the coronavirus, but believes that we should all do what we can to help those around us. Dole is committed to continuing these efforts during this crisis.
Vince Hall, CEO of Feeding San Diego, an organization whose mission is to connect every person facing hunger with nutritious meals, shared his comments on Dole’s actions.
“While medical providers and first responders battle the COVID-19 crisis, Feeding San Diego is battling unprecedented hunger across San Diego County. One of our most important allies in this fight is Dole Food Company, a significant employer at the Port of San Diego. Dole continues to regularly donate large amounts of nutritious fresh fruit, especially bananas, which are very popular in the community and contribute to good health. Dole is to be commended for helping Feeding San Diego take care of those in need all year round, but especially during the current health crisis.”
In addition to San Diego, Dole has made donations in other U.S. cities including New York, Philadelphia, Charlotte, Houston, Los Angeles.
In Latin America, where Dole grows its tropical fruits, such as bananas and pineapple, the crisis is also hitting hard, and the company is supporting those rural communities where food security is most at risk. In the Aguan Valley of Honduras, for example, in addition to fruit Dole is distributing household staples such as rice, beans and cooking oil to employees and local communities. Beyond food, the company is also providing masks, sanitizing gel, testing kits and other health supporting supplies. Similar support is happening for communities in Costa Rica, Ecuador, Guatemala and Colombia including the provision of over 15,000 personal hygiene kits to aid in the prevention of infection.
“As an important local employer, it is our duty to support local communities. The consequences of this crisis are just starting to be felt here and the need for social support will continue to be felt in the weeks and months to come,” stated Renato Acuña, President of Dole Fresh Fruit Latin America. “Our local foundations and those of our associated producers are actively working on the ground and on the front line of this crisis, and Dole will provide additional support as long as necessary.”
The Dale Foundation, funded by Dole and its Ecuadorian growers, is using its medical staff and facilities to get the word out to the community on the importance of COVID-19 prevention, identifying high risk citizens to help them undertake the proper care, advancing purchases of medication that can help with respiratory illness, and continuing to operate its health clinics and provide remote medical services for its patients in the agricultural community.
Dole is also supporting those working on the front lines of the crisis by donating to hospitals in various countries where it operates and working with civil authorities to provide local aid.
For example, in the U.S., Dole has joined national produce distributor PRO*ACT, and other produce partners, to bring fresh produce to the tables of healthcare workers and their families during the COVID-19 crisis. The ‘Feeding our Frontlines’ program (www.producepartners.org ) provides boxes of fresh produce for healthcare employees to take home at the end of a long shift as a way of saying “thank you” to those taking care of us."
About Dole Food Company
Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200416005885/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
